Liu Yi, Zhou Wei, Zhong De-Wu
Department of Hepatobiliary Surgery,The Second Xiangya Hospital, Central South University, Renmin Road No.139, Changsha City, 410011 Hunan Province, China.
Tumour Biol. 2012 Aug;33(4):1191-9. doi: 10.1007/s13277-012-0364-9. Epub 2012 Mar 7.
The associations between four common genetic polymorphisms of transforming growth factor-β1 (TGF-β1 -509 C > T, +869 T > C, +915 G > C, and -800 G > A) and risk of colorectal tumor (including adenoma and cancer) have been widely studied. To date, no conclusions could be available because of controversial results reported. Thus, we conducted a meta-analysis to further assess the associations. We searched the databases of Medline, Embase, and Wangfang to identify eligible studies, and latest update was on January 1, 2012. Odds ratio (OR) and 95% confidence interval (95%CI) were calculated to present the associations. Our meta-analysis indicated that TGF-β1 -509 C > T, +869 T > C, +915 G > C, and -800 G > A were not associated with risk of colorectal adenoma (OR = 0.89 for C carriers vs. TT for -509 C > T, 1.03 for C carriers vs. TT for +869 T > C, 1.09 for C carriers vs. GG for +915 G > C, and 1.19 for A carriers vs. GG for 800 G > A). However, C allele of TGF-β1 -509 C > T and A allele of -800 G > A were associated with increased risk of colorectal cancer (CRC), and OR (95%CI) was 1.23 (0.99-1.52) for CC vs. TT for -509 C > T and 6.64 (3.46-12.72) for A carriers vs. GG. The positive association between -509 C allele and risk of CRC was more obvious when subgroup analyses were conducted for population-based and large sample-sized studies as well as Caucasians. In contrast, we did not observed any associations between TGF-β1 +869 T > C, +915 G > C, and risk of CRC. This study indicated that C allele of TGF-β1-509 C > T and A allele of -800 G > A might contribute to the increased risk of CRC, and could be used as two of genetic marks for screening individuals at high risk of CRC. Because of modest limitation, large sample-sized studies were required to confirm the findings.
转化生长因子-β1（TGF-β1 -509 C>T、+869 T>C、+915 G>C和-800 G>A）的四种常见基因多态性与结直肠肿瘤（包括腺瘤和癌）风险之间的关联已得到广泛研究。迄今为止，由于报道的结果存在争议，尚无定论。因此，我们进行了一项荟萃分析以进一步评估这些关联。我们检索了Medline、Embase和万方数据库以确定符合条件的研究，最新更新时间为2012年1月1日。计算优势比（OR）和95%置信区间（95%CI）以呈现这些关联。我们的荟萃分析表明，TGF-β1 -509 C>T、+869 T>C、+915 G>C和-800 G>A与结直肠腺瘤风险无关（对于-509 C>T，C携带者与TT相比的OR=0.89；对于+869 T>C，C携带者与TT相比的OR=1.03；对于+915 G>C，C携带者与GG相比的OR=1.09；对于800 G>A，A携带者与GG相比的OR=1.19）。然而，TGF-β1 -509 C>T的C等位基因和-800 G>A的A等位基因与结直肠癌（CRC）风险增加相关，对于-509 C>T，CC与TT相比的OR（95%CI）为1.23（0.99 - 1.52），对于A携带者与GG相比为6.64（3.46 - 12.72）。当对基于人群和大样本量的研究以及高加索人进行亚组分析时，-509 C等位基因与CRC风险之间的正相关更为明显。相比之下，我们未观察到TGF-β1 +869 T>C、+915 G>C与CRC风险之间存在任何关联。本研究表明，TGF-β1 -509 C>T的C等位基因和-800 G>A的A等位基因可能导致CRC风险增加，并可作为筛查CRC高危个体的两个遗传标记。由于存在一定局限性，需要大样本量研究来证实这些发现。
